DDrare: Database of Drug Development for Rare Diseases

Dapagliflozin (DrugBank: Dapagliflozin)

2 diseases

ID	Disease name (Link within this page)	Number of trials
49	Systemic lupus erythematosus	1
222	Primary nephrotic syndrome	1

49. Systemic lupus erythematosus [ 827 clinical trials, 638 drugs, (DrugBank: 168 drugs), 108 drug target genes, 191 drug target pathways]

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 827 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800015030	2018-03-01	2018-03-01	A Clinical Trial on Safety and effect of Dapagliflozin to Control Blood Glucose Levels in Systemic Lupus Erythematosus	The Safety of SGLT2-i Dapagliflozin on Treating Blood Glucose Levels in SLE	Systemic Lupus Erythematosus	Case series:add-on or replace dapagliflozin;	Dept. Rheumatology, Renji Hospital South Campus	NULL	Pending	18	70	Both	Case series:35;	4 (Phase 4 study)	China

222. Primary nephrotic syndrome [ 234 clinical trials, 241 drugs, (DrugBank: 78 drugs), 59 drug target genes, 185 drug target pathways]

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 234 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02585804 (ClinicalTrials.gov)	September 2015	22/10/2015	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects	Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study	Focal Segmental Glomerulosclerosis	Drug: Dapagliflozin	University Health Network, Toronto	AstraZeneca;University of Toronto;Toronto General Hospital	Completed	18 Years	N/A	All	10	Phase 4	Canada